Taxanes trigger cancer cell killing in vivo by inducing non-canonical T cell cytotoxicity

Area of Science:

• Immunology
• Pharmacology
• Oncology

Background:

• Taxanes are widely used chemotherapies with known toxicities, including peripheral neuropathy.
• The precise in vivo mechanism of taxane action, particularly concerning immune cell engagement, remains incompletely understood.
• Current taxane treatments carry risks of side effects without guaranteed clinical benefit.

Purpose of the Study:

• To elucidate the in vivo mode of action of taxanes.
• To investigate the interaction between taxanes and T cells in cancer treatment.
• To develop novel therapeutic strategies that leverage taxane-induced anti-tumor immunity while mitigating systemic toxicity.

Main Methods:

• In vivo studies to observe taxane effects on T cells and cancer cells.
• Analysis of T cell activation and cytotoxic mechanisms.
• Development and testing of ex vivo T cell pre-treatment strategies.

Main Results:

• Taxanes directly induce T cells to kill cancer cells via a T cell receptor-independent pathway.
• Taxane-activated T cells release cytotoxic extracellular vesicles that selectively induce apoptosis in tumor cells.
• Healthy epithelial cells are spared from taxane-induced T cell-mediated cytotoxicity.
• Ex vivo pre-treatment of T cells with taxanes followed by adoptive transfer demonstrates therapeutic potential with reduced systemic toxicity.

Conclusions:

• Taxanes possess a previously unrecognized immunomodulatory function, directly activating T cells for cancer cell killing.
• This non-canonical T cell activation offers a targeted approach to cancer therapy.
• Harnessing taxane-primed T cells presents a promising strategy to enhance anti-tumor efficacy and circumvent the systemic side effects associated with conventional chemotherapy.